Humboldt Fund

Humboldt Fund Research Investment Thesis Humboldt Fund is an exclusive synthetic biology venture capital fund that invests in early-stage companies replacing industrial inputs with biology-based alternatives. The fund is led by a UCSF-trained PhD cell biologist with deep scientific expertise and global reach spanning Latin America and Europe. The thesis recognizes that synthetic biology is poised to transform how the world manufactures chemicals, materials, foods, and medicines—addressing a $25 trillion market opportunity across multiple trillion-dollar subsectors. The firm believes in applying revolutionary technologies to improve life while generating substantial economic returns. They focus on the intersection of engineering with physical and life sciences, backing visionary scientific synthesis that creates technological advances disrupting global conventions. Sector and Technology Focus Humboldt Fund is exclusively focused on synthetic biology as a general-purpose technology with applications across multiple industries: Primary Focus Areas: Industrial biotechnology and bio-based chemicals (replacing petroleum-derived inputs) Alternative protein and sustainable food production Synthetic biology tools and enabling technologies CRISPR and gene editing platforms Cellular engineering and therapeutics Biomanufacturing and bioprocessing Notable Portfolio Categories: Food tech and alternative proteins (NotCo, Meatable, Mission Barn, Mycoworks leather) DNA synthesis and genomics tools (Ansa Bio, Metagenomi) Therapeutics leveraging synthetic biology (Finch Therapeutics, Affini-T) Diagnostic and life sciences tools (Concerto Biosciences, Bright Seed, Endpoint Health) Agricultural biotechnology and phage-based solutions (Phage Lab, Tierra Biosciences) Stage Focus Humboldt Fund targets early-stage investments , primarily: Pre-Seed : $500K-$1M for prototype validation and team formation Seed : $1M-$2M for clinical/market validation and initial commercialization Series A : $3M-$10M for scale-up and market expansion They have made follow-on investments in later stages when companies are executing well, but are primarily focused on identifying and supporting companies from earliest stages. Check Size and Investment Pattern Typical Investment Range: $500K - $1M per investment Pre-Seed: $500K-$1M Seed: $1M-$2M Co-investments in Series A: up to $5M-$10M Tracxn data indicates they have made 6 Series A investments with an average round size of $40.2M, suggesting they participate in later rounds opportunistically but don't focus there. They have made 5 investments in seed stage and 3 in early-stage rounds, indicating strong seed-stage expertise. Lead Tendency Humboldt Fund demonstrates a mixed lead tendency : They often co-lead rounds with other prominent investors (Leaps by Bayer, Mubadala Capital, Horizons Ventures) They lead pre-seed and seed rounds for early companies They participate in Series A rounds as co-investors Their portfolio includes several unicorns and successful exits, indicating strong operational support and follow-on commitment Recent Activity and Fund Status Fund Status: Actively deploying Notable Recent Investments (2024-2025): Affini-T Therapeutics (November 2024-2025): Participated in $175M Series financing for T-cell therapies Portfolio company funding announcements: Multiple seed and Series A completions Continued investments in synthetic biology companies across food, diagnostics, and therapeutics Exits and Successes: NotCo: Unicorn status (valued $2B+), AI-powered alternative food company Metagenomi: CRISPR-based therapeutics platform, co-founded by UC Berkeley scientists Finch Therapeutics: Microbiome therapeutics, IPO (now traded publicly) Mycoworks: Lab-grown leather alternative Numerous acquisitions and ongoing growth-stage companies Fund Timeline: First close in 2024, indicating relatively recent fund formation, though founders have been investing in the space since 2020. Team The fund is led by three complementary partners with deep expertise: Sebastian Bernales - PhD Cell Biologist, General Partner UCSF-trained PhD cell biologist Deep scientific and research credentials Provides clinical and scientific due diligence Benjamin Quiroga - General Partner Business expertise from Universidad Católica Focused on commercial strategy and partnerships Francisco Dopazo - General Partner MBA from MIT Sloan Extensive background spanning consulting and finance Experience managing over $2 billion in capital Brings operational and financial expertise Geographic and Industry Preferences Geographic Focus: Primary: US West Coast (San Francisco Bay Area headquarters in New York with operations focus) Secondary: Global reach into Latin America and Europe due to founder networks and investment focus Selective investments across major biotech hubs Industry Preferences: Synthetic biology-only focus (no other sectors) Companies creating transformative bio-based solutions Teams with founder-scientists and deep domain expertise Decision Process Decision Structure: Partnership-based with regular investment committee meetings Typical Timeline: 4-8 weeks for pre-seed decisions, 6-12 weeks for seed-stage Warm Introductions: Strongly preferred; cold outreach conversion rates are low Industry Network: Extensive connections to synthetic biology experts, founders, and academic institutions Founder and Company Preferences Humboldt Fund favors: Founder Profile: Scientists and engineers with PhD-level expertise, previously founded companies or published research, deep domain knowledge in biotechnology or synthetic biology Company Stage: Validated science, working prototypes or initial customer traction, experienced founding teams Business Model: Products with defensible intellectual property, clear regulatory pathway (where applicable), large addressable markets Anti-thesis: Later-stage capital seeking (Series B+) - outside fund thesis Service-based models without product innovation Teams without scientific founders or domain expertise Non-synbio applications of biotechnology Notable Portfolio Companies Active Investments (Sample): Metagenomi - CRISPR-based therapeutics platform Finch Therapeutics - Microbiome therapeutics (IPO) Ansa Biotechnologies - Enzymatic DNA synthesis for synthetic biology research NotCo - AI-powered alternative food company (Unicorn) Mycoworks - Lab-grown leather alternatives Meatable - Cultivated meat company Mission Barn - Precision fermentation for dairy alternatives Bright Seed Bio - Fermentation optimization Affini-T Therapeutics - Synthetic biology-based T-cell therapies Concerto Biosciences - Microfluidics for biological screening Tierra Biosciences - Agricultural biotechnology Endpoint Health - AI-driven diagnostics Phage Lab - Phage-based therapies and solutions Finless Foods - Cultivated seafood GC Therapeutics - Gene and cell therapies Tracxn Data: Portfolio includes 50+ companies total, with 1 unicorn, 2 IPOs, and 2+ acquisitions. Market Opportunity and Conviction The fund focuses on synthetic biology addressing a $25 trillion total addressable market: $12 trillion in industrial chemicals and materials $7 trillion in food and agriculture $4 trillion in pharmaceuticals and therapeutics $2 trillion in specialized applications They believe this represents one of the largest untapped opportunities in technology-enabled innovation. Operational Support and Value-Add Beyond capital, Humboldt Fund provides: Deep scientific and technical mentorship from PhD advisors Global network for partnerships and customer discovery Expertise in regulatory pathways (FDA, EPA, international) Connections to manufacturing and commercialization partners Strategic guidance on go-to-market for biology-based products Fund Performance Indicators Fund Size: Data suggests focused fund with ability to deploy meaningful capital Deployment Rate: Regular announcements of new investments, indicating active capital deployment Portfolio Support: Evidence of strong follow-on support and successful exits Market Recognition: Recognized as leading synthetic biology VC by industry sources (Bay Bridge Bio, Excedr, others) Decision Timeline and Process Pre-Seed: 4-6 weeks typical timeline Seed: 6-8 weeks typical timeline Follow-on Rounds: Evaluated separately with board participation Warm Introduction Requirements Warm introductions strongly preferred. The fund focuses on founder networks and existing investor relationships. Cold outreach is possible but less likely to gain traction. Ideal introductions come from: Existing portfolio company founders Academic collaborators at UCSF, UC Berkeley Fellow investors in the synthetic biology space Industry experts and conference contacts Investment Conviction and Thesis Evolution Humboldt Fund is bullish on synthetic biology as a foundational technology. Recent market trends support this: Synthetic biology received $17.3B in VC funding in 2025 (3x the amount from 2022) FDA approved three synbio-derived ingredients in 2025 alone Major exits and unicorn valuations validating the sector's maturity The fund is well-positioned as consolidation and scaling accelerates in synthetic biology.